Adaptive Biotechnologies Corp (ADPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adaptive Biotechnologies Corp (ADPT) has a cash flow conversion efficiency ratio of -0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.13 Million) by net assets ($204.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ADPT market cap overview for the company's overall valuation and market capitalisation.
Adaptive Biotechnologies Corp - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Adaptive Biotechnologies Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adaptive Biotechnologies Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adaptive Biotechnologies Corp ranked by their cash flow conversion efficiency. Explore Adaptive Biotechnologies Corp cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IJM Corporation Bhd
KLSE:3336
|
-0.007x |
|
KANSAI PAINT SPON.ADR/1/2
F:KAP0
|
N/A |
|
Upstart Holdings Inc
NASDAQ:UPST
|
0.136x |
|
Gujarat Gas Limited
NSE:GUJGASLTD
|
0.054x |
|
Haemonetics Corporation
NYSE:HAE
|
0.089x |
|
Legend Holdings Corporation
F:1PC
|
-0.009x |
|
Inari Amertron Bhd
KLSE:0166
|
0.027x |
|
Tecnicas Reunidas
MC:TRE
|
0.027x |
Annual Cash Flow Conversion Efficiency for Adaptive Biotechnologies Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of Adaptive Biotechnologies Corp from 2017 to 2024. View Adaptive Biotechnologies Corp stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $202.49 Million | $-95.21 Million | -0.470x | +7.27% |
| 2023-12-31 | $308.28 Million | $-156.32 Million | -0.507x | -27.94% |
| 2022-12-31 | $464.10 Million | $-183.94 Million | -0.396x | -24.24% |
| 2021-12-31 | $604.10 Million | $-192.73 Million | -0.319x | -58.42% |
| 2020-12-31 | $743.27 Million | $-149.68 Million | -0.201x | -155.99% |
| 2019-12-31 | $571.04 Million | $205.40 Million | 0.360x | +187.81% |
| 2018-12-31 | $-258.11 Million | $-32.26 Million | 0.125x | -19.47% |
| 2017-12-31 | $-224.62 Million | $-34.86 Million | 0.155x | -- |
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diag… Read more